Citadel Embolization Device Study

NAActive, not recruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

July 18, 2019

Primary Completion Date

November 15, 2026

Study Completion Date

November 15, 2026

Conditions
Unruptured Wide-neck Aneurysms
Interventions
DEVICE

Citadel Embolization Device

The Citadel Embolization Device is intended to endovascularly obstruct or occlude blood flow in intracranial aneurysms.

Trial Locations (26)

10021

Weill Cornell, New York

10467

Montefiore Medical Center, New York

19104

University of Pennsylvania Hospital, Philadelphia

19107

Thomas Jefferson University, Philadelphia

26506

West Virginia University Hospital, Morgantown

32207

Baptist Health, Jacksonville

32608

University of Florida, Gainesville

33136

University of Miami/Jackson Memorial, Miami

33606

Tampa General Hospital, Tampa

40503

Baptist Health, Lexington

40506

University of Kentucky, Lexington

44195

Cleveland Clinic, Cleveland

46202

Indiana Methodist, Indianapolis

48532

McLaren Health Center, Flint

49503

Spectrum Health, Grand Rapids

60611

Northwestern University, Chicago

63110

Washington University, St Louis

66160

Kansas University Medical Center, Kansas City

80113

RIA Neurovascular, Englewood

85710

Carondelet St. Joseph Hospital, Tucson

90048

Cedars-Sinai Medical Center, Los Angeles

94114

California Pacific Medical Center, San Francisco

94143

UCSF Medical Center, San Francisco

94598

John Muir Health, Walnut Creek

98104

University of Washington, Seattle

01605

UMass Memorial Health, Worcester

All Listed Sponsors
lead

Stryker Neurovascular

INDUSTRY